Our experience with treatment of myeloma with thalidomide

Transfuze Dnes

Volumn 8, Issue 1, 2002, Pages 13-19

  Neuwirtova R ^a   Spicka I ^a   Karban, J ^a   Rotterova J ^a   Cmunt, E ^a   Valkova V ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Multiple myeloma; Resistant myeloma; Thalidomide; Treatment

Indexed keywords

ALKALI; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; CYCLOPHOSPHAMIDE; CYTOKINE; CYTOSTATIC AGENT; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; HEMOGLOBIN; IDARUBICIN; MELPHALAN; PREDNISONE; THALIDOMIDE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BONE PAIN; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG TOLERABILITY; EDEMA; EXPERIENCE; FEMALE; HUMAN; IMMUNOMODULATION; MALE; MYELOMA; MYELOMA CELL; NEUTROPENIA; OSTEOLYSIS; PARAPROTEINEMIA; PARESTHESIA; PLASMAPHERESIS; POLYNEUROPATHY; REMISSION; SOMNOLENCE; STAGING; STEM CELL TRANSPLANTATION; TREATMENT FAILURE;

EID: 0036211408     PISSN: 12129887     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Thalidomide: Therapeutic potential in hematological malignancies
2. Bone marrow angiogenesis and progression in multiple myeloma
3. Antitumor activity of thalidomide in refractory multiple myeloma
4. Pharmacology of thalidomide
5. Thalidomide and its analogs overcome drug rezistence of human multiple myeloma cells to conventional therapy
6. Thalidomide treatment in multiple myeloma
7. Thalidomide - A revival story
8. New concepts in the pathogenesis of multiple myeloma
9. Effect of thalidomide on myeloma cell apoptosis and VEGF secretion
10. Multiple myeloma: Biologic research leading to new diagnostic and therapeutic strategies?
11. Global gene expression analysis shows loss of c-myc and IL-6 receptor gene mRNA after exposure of myeloma to thalidomide and IMiD
12. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
13. Advances in disease biology: Therapeutic implications
14. Frequent good partial remisions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma
15. Clinical experiance with thalidomide in multiple myeloma: Phase II trial results in refractory disease and ongoing studies
16. Thalidomide for rezistent and relaps in myeloma
17. Efficacy of low dose thalidomide in multiple myeloma
18. Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma
19. Thalidomide with dexamethasone for resistant multiple myeloma
20. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy
21. Coumadin in deep-vein thrombosis prophylaxis in patients treated with thalidomide/dexamethasone
22. Poruchy antikoagulačních systémů a fibrinolýzy u monoklonálních gamapatiís-další mechanismus interference paraproteinu s hemostázou
23. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes